Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

627 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.
Autar RS, Ananworanich J, Apateerapong W, Sankote J, Hill A, Hirschel B, Cooper D, Lange J, Phanuphak P, Ruxrungtham K, Burger D. Autar RS, et al. Among authors: hirschel b. J Antimicrob Chemother. 2004 Oct;54(4):785-90. doi: 10.1093/jac/dkh415. Epub 2004 Aug 25. J Antimicrob Chemother. 2004. PMID: 15329366 Clinical Trial.
Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mahanontharit A, Ubolyam S, Cooper D, Phanuphak P, Ruxrungtham K. Ananworanich J, et al. Among authors: hirschel b. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-9. J Acquir Immune Defic Syndr. 2005. PMID: 16044002 Clinical Trial.
A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
Ananworanich J, Hill A, Siangphoe U, Ruxrungtham K, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Nuesch R, Cooper DA, Hirschel B; Staccato Study Group. Ananworanich J, et al. Among authors: hirschel b. Antivir Ther. 2005;10(6):761-7. Antivir Ther. 2005. PMID: 16218176 Clinical Trial.
Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial.
Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S, Ruxrungtham K, Furrer H, Cooper D, Hirschel B, Bernasconi E, Cavassini M, Ebnöther C, Fagard C, Genné D, Khanna N, Perrin L, Phanupak P, Ubolyam S, Vernazza P, Yerly S; Swiss HIV Cohort Study. Ananworanich J, et al. Among authors: hirschel b. AIDS. 2003 Oct 17;17(15):F33-7. doi: 10.1097/00002030-200310170-00001. AIDS. 2003. PMID: 14523294 Clinical Trial.
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.
Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genné D, Nüesch R, Vernazza P, Bernasconi E, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B; Staccato Study Group; Swiss HIV Cohort Study. Ananworanich J, et al. Among authors: hirschel b. Lancet. 2006 Aug 5;368(9534):459-65. doi: 10.1016/S0140-6736(06)69153-8. Lancet. 2006. PMID: 16890832 Clinical Trial.
Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
Ananworanich J, Hirschel B, Sirivichayakul S, Ubolyam S, Jupimai T, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Schutz M, Snowden W, Ruxrungtham K; Staccato Study Team. Ananworanich J, et al. Among authors: hirschel b. Antivir Ther. 2006;11(5):631-5. Antivir Ther. 2006. PMID: 16964832 Clinical Trial.
627 results